Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Work In Process (2016 - 2018)

Anika Therapeutics (ANIK) has disclosed Work In Process for 8 consecutive years, with $5.9 million as the latest value for Q3 2018.

  • On a quarterly basis, Work In Process fell 9.38% to $5.9 million in Q3 2018 year-over-year; TTM through Sep 2018 was $5.9 million, a 9.38% decrease, with the full-year FY2017 number at $6.1 million, up 9.05% from a year prior.
  • Work In Process was $5.9 million for Q3 2018 at Anika Therapeutics, down from $6.3 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $6.6 million in Q3 2017 to a low of $2.2 million in Q2 2014.
  • A 5-year average of $4.8 million and a median of $5.6 million in 2016 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: surged 94.43% in 2016, then fell 9.38% in 2018.
  • Anika Therapeutics' Work In Process stood at $3.0 million in 2014, then skyrocketed by 85.99% to $5.7 million in 2015, then decreased by 1.71% to $5.6 million in 2016, then rose by 9.05% to $6.1 million in 2017, then decreased by 1.88% to $5.9 million in 2018.
  • Per Business Quant, the three most recent readings for ANIK's Work In Process are $5.9 million (Q3 2018), $6.3 million (Q2 2018), and $5.9 million (Q1 2018).